New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 9, 2012
10:29 EDTDOW, AFFX, VECO, SMG, FOSL, DMD, AIG, PRTS, UA, MGLN, EZPW, CPE, HSY, STJ, IQNTOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AIG (AIG) upgraded to Buy from Neutral at Goldman... Affymetrix (AFFX) upgraded to Equal Weight from Underweight at Morgan Stanley... Callon Petroleum (CPE) upgraded to Outperform from Neutral at RW Baird... Demand Media (DMD) upgraded to Buy from Neutral at Citigroup... Dow Chemical (DOW) upgraded to Overweight from Equal Weight at Morgan Stanley... EZCORP (EZPW) upgraded to Neutral from Underperform at Sterne Agee... Fossil (FOSL) upgraded to Buy from Hold at Benchmark Co... Inteliquent (IQNT) upgraded to Outperform from Neutral at RW Baird... Magellan Health (MGLN) upgraded to Buy from Neutral at BofA/Merrill... Scotts Miracle-Gro (SMG) upgraded to Market Perform from Underperform at BMO Capital... St. Jude Medical (STJ) upgraded to Overweight from Equal Weight at Morgan Stanley... Under Armour (UA) upgraded to Buy from Neutral at UBS... Veeco (VECO) upgraded to Overweight from Neutral at Piper Jaffray... Hershey (HSY) upgraded to Buy from Hold at Argus... U.S. Auto Parts (PRTS) upgraded to Buy from Neutral at Roth Capital.
News For AIG;AFFX;CPE;DMD;DOW;EZPW;FOSL;IQNT;MGLN;SMG;STJ;UA;VECO;HSY;PRTS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 21, 2015
17:08 EDTDMDDemand Media Chief Technology Officer Brian Pike to assume COO role
Demand Media announced that Brian Pike, its Chief Technology Officer, will now also serve as COO. The company also announced that Julie Campistron, EVP, Media, has decided to step down on June 5 after eight years with Demand Media, but will continue consulting for the company through August, while Scott Boecker, EVP, Marketplaces, is leaving to pursue another opportunity.
07:14 EDTSMGBMO Capital to hold a conference
Subscribe for More Information
May 20, 2015
18:01 EDTEZPWEZCORP receives written notice from NASDAQ
Subscribe for More Information
17:45 EDTEZPWEZCORP sees preliminary Q2 net revenue $312M
The company said, "We anticipate that cash flow from operations and our cash on hand will be adequate to fund our contractual obligations, planned store growth, capital expenditures and working capital requirements during the remainder of the fiscal year. In addition, we expect to continue to obtain local financing to fund Grupo Finmart’s lending growth and our Mexican pawn growth."
08:48 EDTDOWNomura taking a bullish long-term view on ethylene
Nomura believes the market is overestimating the potential decline in ethylene/polyethylene margins. The sees the current global tightness as a bullish sign for 2016-2017 and recommends positioning Dow Chemical (DOW) over LyondellBasell (LYB) due to lower reliance on an upside ethylene margin story.
08:09 EDTSTJSt. Jude Medical management to meet with Leerink
Subscribe for More Information
08:05 EDTAIGAIG acquires controlling stake in ING Employee Benefits Global Network
Subscribe for More Information
07:30 EDTSMGMonsanto, Scotts Miracle-Gro expand long-standing agreement
Monsanto Company (MON) and The Scotts Miracle-Gro Company (SMG) announced the two companies have extended their nearly two-decade long partnership in the lawn and garden consumer market. Since 1999, Scotts Miracle-Gro, through one of its subsidiaries, has served as Monsanto's exclusive agent for the marketing and distribution of Roundup® non-selective herbicides in the consumer lawn and garden market within the United States and select international markets. Today’s agreement will unlock additional value in the Roundup brand in the lawn and garden segment by providing Scotts with an extended license to use the Roundup brand in new lawn and garden product categories and broaden their marketing rights into new geographies. As part of the extension, Monsanto also renewed and expanded the terms of its marketing agreement with Scotts and provided preferred access to Monsanto’s R&D pipeline for lawn and garden. Under the agreement, Scotts will pay Monsanto a one-time upfront payment of $300M in exchange for a Roundup® brand license, extended agency agreement and technology agreement.
07:16 EDTSTJLeerink to hold a booth tour at EuroPCR
Subscribe for More Information
07:06 EDTSMGScotts Miracle-Gro announces agreement with Monsanto to extend Roundup brand
Scotts Miracle-Gro (SMG) announced an agreement with Monsanto (MON) that offers opportunities to extend the Roundup brand into new lawn and garden categories and geographies. The two companies also have reached a technology sharing agreement and have made amendments to the existing Roundup Agency Agreement that provide greater long-term security for ScottsMiracle-Gro. Key highlights to the agreements provide ScottsMiracle-Gro with enhanced security, as termination of the agreement no longer includes specific performance criteria. In the event Monsanto terminates the agreement, in certain circumstances, the company would receive a termination fee of no less than $200M and would retain its agency rights for at least 5 years. ScottsMiracle-Gro has agreed to pay Monsanto $300M in connection with these and other amendments to the current Agency Agreement and the brand extension and joint technology agreements. Financing will be accommodated under the company's existing credit facility. Because the ability to introduce new products and enter new geographies could take several years, the amended agreement modifies the existing commission structure. The result of the new structure is expected to offset financing costs and the expenses required for the development of new Roundup products and services.
05:29 EDTSTJSt. Jude Medical announces preliminary results from ILUMIEN I and ILUMIEN II
St. Jude Medical announced preliminary results from the ILUMIEN I trial and final results from the ILUMIEN II clinical study. Taken together, the findings from both studies show that with resolution up to 10 times higher than intravascular ultrasound, optical coherence tomography imaging can help improve stent selection and deployment, better support clinical decision-making and improve patient outcomes. In the prospective study to date examining OCT’s impact on clinical decisions and their associated outcomes, ILUMIEN I assessed 418 patients suffering stable or unstable angina or non-ST segment elevation myocardial infarction. The study’s 12-month data shows: OCT guidance conducted either pre- or post-PCI altered physician decision-making in 65% of patients; Pre-PCI OCT altered treatment planning in 55% of patients and led to changes in decisions related to stent length and diameter; OCT imaging was associated with a reduction of in-hospital MI when used pre- and post-PCI to change the procedural strategy. The ILUMIEN II study was designed to determine whether OCT guidance results in a comparable degree of stent expansion as IVUS imaging. After an analysis of OCT-guided stenting or IVUS-guided stenting in 940 patients from the ILUMIEN I and ADAPT-DES studies, the degree of stent expansion was found to be comparable between OCT and IVUS imaging. The study’s data shows OCT and IVUS guidance were also associated with comparable rates of major stent malapposition, tissue protrusion and stent edge dissection.
May 19, 2015
08:05 EDTSTJSt. Jude Medical announces Canadian launch of Prodigy Chronic Pain System
Subscribe for More Information
07:44 EDTCPECowen sees energy M&A focusing on accretive deals from non-core assets
Subscribe for More Information
May 15, 2015
17:15 EDTAIGPaulson & Co. gives quarterly update on stakes
Subscribe for More Information
14:20 EDTSTJSt. Jude Medical reports positive results from CardioMEMS HF System
Subscribe for More Information
14:01 EDTSTJSt. Jude Medical reports positive results from Allure Quadra CRT-P System
St. Jude Medical announced the presentation of important data supporting the first and only quadripolar cardiac resynchronization therapy pacemaker system in the U.S., during the Heart Rhythm Society's 36th annual scientific sessions. The Allure Quadra CRT-P system, with the Quartet Quadripolar LV Lead is associated with a 63% reduction in the need to replace the lead or deactivate CRT following implant. Quadripolar LV pacing using SJM quadripolar CRT-Ds or CRT-Ps and an SJM quadripolar lead provides physicians with multiple pacing options to avoid phrenic nerve stimulation and allow for optimal treatment delivery without the need to replace or deactivate the therapy. An analysis evaluating more than 3,000 patients implanted with a CRT-P (1,325 with a quadripolar lead vs. 1,930 with a bipolar lead) looked at whether the known decreased need to replace or deactivate LV leads associated with SJM quadripolar CRT-Ds and the Quartet LV lead also extends to St. Jude Medical quadripolar CRT-Ps. The retrospective data analysis was presented in a session titled Quadripolar Leads are Associated with Fewer LV Lead Replacements and Deactivations in CRT-P Patients by Dr. Mintu P. Turakhia, who led the investigation. The data show that patients with the Quartet LV lead were 63% less likely to undergo lead replacement or deactivation of CRT compared to the patients with bipolar leads.
11:08 EDTDOWOmega Advisors gives quarterly update on stakes
NEW STAKES: Targa Resources (TRGP), Targa Resources Partners (NGLS), Humana (HUM), Dow Chemical (DOW), and Twenty-First Century Fox (FOXA). INCREASED STAKES: Kinder Morgan (KMI), Chimera Investment Corporation (CIM), AerCap Holdings (AER), Shire (SHPG), and KKR & Co. (KKR). DECREASED STAKES: eBay (EBAY), Altisource Portfolio Solutions (ASPS), Caesars Entertainment (CZR), Navient (NAVI), and TerraForm Power (TERP). LIQUIDATED STAKES: HCA Holdings (HCA), Gilead (GILD), Cabot Oil & Gas (COG), and Apple (AAPL).
10:55 EDTAIGJANA Partners gives quarterly update on stakes
Subscribe for More Information
08:45 EDTSTJSt. Jude Medical management to meet with Leerink
Subscribe for More Information
08:41 EDTSTJSt. Jude Medical management to meet with Leerink
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use